Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2024-05-30
2031-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
NCT02673398
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT03101748
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
NCT03329937
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT01670877
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
NCT05243641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine efficacy of neoadjuvant neratinib in combination with endocrine therapy.
SECONDARY OBJECTIVES:
I. Determine additional efficacy outcomes of neoadjuvant neratinib in combination with endocrine therapy.
II. Compare the safety and tolerability of neratinib plus endocrine therapy.
CORRELATIVE OBJECTIVE:
I. Establish HER2-mutant invasive lobular carcinoma (ILC) organoids.
OUTLINE: Patients are randomized to 1 of 2 treatments.
TREATMENT A: Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib orally (PO) daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast magnetic resonance imaging (MRI) prior to surgery.
TREATMENT B: Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
After completion of study treatment, patients are followed up for 4 weeks after study drugs interruption.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A (endocrine therapy)
Patients receive standard of care endocrine therapy over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
Endocrine Therapy
Undergo endocrine therapy
Biopsy of breast
Undergo breast biopsy
Neratinib
Taken by mouth
Biospecimen Collection
Undergo collection of blood samples
Mammogram
Undergo Mammogram
Magnetic Resonance Imaging
Undergo breast Magnetic Resonance Imaging
Breast Surgery
Undergo Breast Surgery
Treatment B (endocrine therapy, neratinib)
Patients receive standard of care endocrine therapy and neratinib PO over 4 weeks for 1 cycle. Patients undergo breast tissue biopsy during the lead-in window/cycle 1. Patients then continue endocrine therapy and neratinib PO daily for 20 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo breast surgery during weeks 24-25. Patients undergo collection of blood samples every 4 weeks while on treatment, at weeks 4 and 24, and at time of surgery. Patients undergo mammogram, ultrasound, or breast MRI prior to surgery.
Endocrine Therapy
Undergo endocrine therapy
Biopsy of breast
Undergo breast biopsy
Neratinib
Taken by mouth
Biospecimen Collection
Undergo collection of blood samples
Mammogram
Undergo Mammogram
Magnetic Resonance Imaging
Undergo breast Magnetic Resonance Imaging
Breast Surgery
Undergo Breast Surgery
Ultrasound
Undergo Ultrasound
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endocrine Therapy
Undergo endocrine therapy
Biopsy of breast
Undergo breast biopsy
Neratinib
Taken by mouth
Biospecimen Collection
Undergo collection of blood samples
Mammogram
Undergo Mammogram
Magnetic Resonance Imaging
Undergo breast Magnetic Resonance Imaging
Breast Surgery
Undergo Breast Surgery
Ultrasound
Undergo Ultrasound
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects aged 18 years or older at signing of informed consent.
* New diagnosis of clinical stage I-III HR+ histologically-proven (i.e. absent or decreased e-cadherin expression) invasive lobular carcinoma
* Synchronous breast tumors are permitted as long as the synchronous tumor is ER+ and HER2-negative.
* ER+ disease defined as ≥1% estrogen receptor (ER) positive consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines)
* At the time of screening, histologically confirmed cancers in patients with previously documented activating HER2 mutation (see Appendix A) confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent laboratory.
* Archival tissue availability (if not available a fresh tumor biopsy will be required) and subject must agree to submission of sample for central testing
* Minimum tumor size of ≥1.5 cm by US, mammogram, MRI imaging, or clinical breast exam
* ECOG performance status 0 or 1
* Patients must have adequate hematologic, hepatic, and renal function. All laboratory tests must be obtained within 1 month of study entry. This includes:
* Estimated glomerular filtration rate of ≥50 mL/min
* Albumin ≥ 2.5 g/dL
* ANC ≥1500/mm\^3
* Platelet count ≥100,000/mm\^3
* HgB ≥ 9 g/dL
* Total serum bilirubin ≤ 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin ≤ 3.0 x ULN, with direct bilirubin ≤ 1.5 x ULN)
* AST and ALT ≤ 3 x ULN
* Pre-, peri-, or post-menopausal, confirmed by history or laboratory testing as needed
* Diagnostic biopsy tissue availability with sufficient tumor to permit NGS (if not available, a fresh biopsy will be required)
* No prior treatment for current diagnosis of breast cancer
* For patients who are not postmenopausal (women) or surgically sterile (absence of ovaries and/or uterus or vasectomy), agreement to remain abstinent or to use two adequate methods of contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal ligation), during the treatment period and for at least 30 days after the last dose of study treatment. Hormone based oral contraceptives are not allowed on study. Postmenopausal is defined as:
* Age ≥ 55 years
* Age ≤ 55 years and amenorrheic for 12 months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone and estradiol in the postmenopausal range. Female participants of childbearing potential are eligible to participate if they agree to use a highly effective method of contraception that has a low user dependency consistently and correctly.
Note: The effects of neratinib on the developing fetus are unknown and endocrine therapy is contraindicated in pregnancy. For this reason and because teratogenic effects have been observed in nonclinical studies and neratinib, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of the study participation, and for 1 month after the last dose of study medication. Should a woman become pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation and 3.5 months after completion of study treatment.
Exclusion Criteria
* Synchronous breast cancer that is estrogen receptor negative OR HER2-amplified OR requires treatment with neoadjuvant chemotherapy per the judgement of the treating physician
* Patients harboring ineligible somatic HER2 mutations, such as those that are subclonal in nature or those resulting in the expression of truncated proteins including alterations that result in premature stop codon or a change in reading frame (ie, frame shift mutations).
* Prior endocrine therapy for breast cancer within the last 2 years
* Women who are pregnant, are planning to become pregnant, or are breast-feeding
* Any investigational treatment for the current diagnosis of breast cancer
* HER2 amplification by FISH (HER2:CEP17 ratio \>2.0) or IHC (HER2 (3+)
* Hepatic function impairment as defined by AST or ALT \> 3x ULN OR total serum bilirubin \> 1.5 (in patients with known Gilbert syndrome, a total bilirubin of \> 3.0 x ULN or direct bilirubin \> 1.5 x ULN)
* Significant chronic gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn's disease, malabsorption, or Grade ≥2 National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events Version 4.0 \[CTCAE version 4.0\] diarrhea of any etiology at baseline.
* Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that could, in the Investigator's judgment, make the patient inappropriate for this study.
* Known hypersensitivity to any component of the investigational product, required combination therapy, or loperamide.
* Unable or unwilling to swallow tablets.
* Unable or unwilling to complete study procedures such as research biopsies or imaging
* Any medical condition that in the judgement of the co-investigator would impair the patient's ability to complete the planned study therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Puma Biotechnology, Inc.
INDUSTRY
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Laura Kennedy
Assistant Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laura Kennedy, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt University/Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory University/ Winship Cancer Institute
Atlanta, Georgia, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
University of Texas, Southwestern
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2023-04468
Identifier Type: REGISTRY
Identifier Source: secondary_id
VICC-NCBRE23172
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.